Clinical Trial Update: Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing fulvestrant plus ribociclib versus physician's choice treatments in HR-positive, HER2-negative metastatic breast cancer after prior adju…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• KISQALI (ribociclib)

Snippet

Sponsor: Yeon Hee Park | Conditions: Breast Cancer Metastatic | Phase 2 | Status: NOT_YET_RECRUITING